Masimo (NASDAQ:MASI) develops innovative monitoring technologies
that significantly improve patient care-helping solve "unsolvable"
problems. In 1995, the company debuted Measure-Through Motion and
Low Perfusion pulse oximetry, known as Masimo SET, and with it
virtually eliminated false alarms and increased pulse oximetry's
ability to detect life-threatening events.
In 2005, Masimo introduced Masimo Rainbow SET, a breakthrough
noninvasive blood constituent monitoring platform that can measure
many blood constituents that previously required invasive
procedures. Rainbow SET continuously and noninvasively measures
total hemoglobin (SpHb(TM)), oxygen content (SpOC(TM)),
carboxyhemoglobin (SpCO(R)), methemoglobin (SpMet(R)), and pleth
variability index (PVI(TM)), in addition to oxyhemoglobin (SpO2),
perfusion index (PI) and pulse rate, allowing early detection and
treatment of potentially life-threatening conditions.
Founded in 1989, Masimo has the mission of "Improving Patient
Outcomes and Reducing Cost of Care by Taking Noninvasive Monitoring
to New Sites and Applications."